We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.76%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$16.2B
AUM Growth
-$2.57B
Cap. Flow
+$150M
Cap. Flow %
0.93%
Top 10 Hldgs %
86.32%
Holding
116
New
17
Increased
25
Reduced
19
Closed
6

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$49.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$43.3M
3
KOD icon
Kodiak Sciences
KOD
+$31.6M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$27.5M
5
ALLK
Allakos
ALLK
+$27.1M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$60M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$48.2M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$10.4M
4
QURE icon
uniQure
QURE
+$9.23M
5
NXTC icon
NextCure
NXTC
+$8.45M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
101
IDEAYA Biosciences
IDYA
$3.44B
$522K ﹤0.01%
126,611
-73,389
-37% -$520K
ADMS
102
DELISTED
Adamas Pharmaceuticals
ADMS
$499K ﹤0.01%
172,630
– –
INFI
103
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$486K ﹤0.01%
580,400
– –
GNFT
104
DELISTED
Genfit
GNFT
$395K ﹤0.01%
+26,696
New +$454K
AFMD
105
DELISTED
Affimed
AFMD
$316K ﹤0.01%
20,000
– –
VIRX
106
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$231K ﹤0.01%
15,905
– –
OVID icon
107
Ovid Therapeutics
OVID
$426M
$207K ﹤0.01%
+69,471
New +$234K
CTMX icon
108
CytomX Therapeutics
CTMX
$690M
$153K ﹤0.01%
20,000
-174,377
-90% -$1.22M
DVAX
109
DELISTED
Dynavax Technologies
DVAX
– –
-75,000
Closed -$429K
NXTC icon
110
NextCure
NXTC
$21.6M
– –
-12,500
Closed -$8.45M
YMAB
111
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-138,514
Closed -$4.33M
FSTX
112
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-153,286
Closed -$969K
TRIL
113
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-1,100,000
Closed -$1.13M
BOLD
114
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-804,720
Closed -$48.2M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Baker Bros. Advisors held 116 positions worth $16.2B, down 14% from $18.8B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q1 2020 filing shows 17 new, 25 increased, 19 reduced and 6 closed positions. Its largest new stake was Adaptimmune Therapeutics: 3,690,307 shares worth $10M. The largest sale was Exact Sciences, an estimated $60M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2020 buy was Adaptimmune Therapeutics: 3,690,307 shares worth $10M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q1 2020, an estimated $49.3M increase.
  • Baker Bros. Advisors's biggest Q1 2020 reduction was Exact Sciences, cutting an estimated $60M.
  • Baker Bros. Advisors fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $48.2M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $16.2B portfolio in Q1 2020.
  • Baker Bros. Advisors opened 17 new positions and closed 6 in Q1 2020.
  • Baker Bros. Advisors's portfolio value fell 14% quarter-over-quarter to $16.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.